mifepristone has been researched along with telapristone acetate in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Attardi, BJ; Blye, RP; Burgenson, J; Hild, SA; Reel, JR | 1 |
| Attardi, BJ; Burgenson, J; Hild, SA; Reel, JR | 1 |
| Christov, K; Mehta, R; Wiehle, RD | 1 |
| Leo, JC; Lin, VC | 1 |
| Spitz, IM | 1 |
| Beckley, EH; Finn, DA; Scibelli, AC | 1 |
| Manyonda, I; Talaulikar, VS | 1 |
| Gamarra-Luques, CD; Goyeneche, AA; Hapon, MB; Telleria, CM | 1 |
| Abraham, T; Arian, SE; Bartels, CB; Cayton, KC; Chuong, FS; Holthouser, K; Segars, JH | 1 |
| Choi, MR; Christov, K; Ivancic, D; Khan, SA; Lee, O | 1 |
| Belland, L; Leyland, N; Murji, A; Singh, SS; von Riedemann, S | 1 |
| Bosland, MC; Clare, SE; Helenowski, I; Hosseini, O; Khan, SA; Kim, JJ; Lee, O; Patel, P; Schipma, MJ; Shidfar, A; Wang, M; Xuei, X | 1 |
4 review(s) available for mifepristone and telapristone acetate
| Article | Year |
|---|---|
Clinical utility of progesterone receptor modulators and their effect on the endometrium.
Topics: Drug Administration Schedule; Endometriosis; Endometrium; Estrenes; Female; Hormone Antagonists; Humans; Leiomyoma; Mifepristone; Norpregnadienes; Oximes; Randomized Controlled Trials as Topic; Receptors, Progesterone; Time Factors; Uterine Neoplasms | 2009 |
Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids.
Topics: Endometrium; Estrenes; Female; Hormone Antagonists; Humans; Hyperplasia; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Mifepristone; Norpregnadienes; Oximes; Receptors, Progesterone | 2012 |
An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review.
Topics: Androgens; Aromatase Inhibitors; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Curcumin; Delayed-Action Preparations; Drugs, Chinese Herbal; Estradiol; Estrenes; Estrogen Receptor Antagonists; Evidence-Based Medicine; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Medroxyprogesterone Acetate; Mifepristone; Neoadjuvant Therapy; Norpregnadienes; Oximes; Plant Extracts; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tea; Uterine Myomectomy; Uterine Neoplasms; Vitamin D; Vitamins | 2016 |
The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
Topics: Contraceptive Agents, Female; Disease Management; Estrenes; Female; Forecasting; Humans; Leiomyoma; Mifepristone; Norpregnadienes; Oximes; Population Growth; Receptors, Progesterone; Steroids; Uterine Neoplasms | 2018 |
8 other study(ies) available for mifepristone and telapristone acetate
| Article | Year |
|---|---|
CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Alkaline Phosphatase; Animals; Binding, Competitive; Enzyme Induction; Hormone Antagonists; Luciferases; Mifepristone; Norpregnadienes; Plasmids; Progestins; Rabbits; Rats; Receptors, Androgen; Receptors, Glucocorticoid; Receptors, Progesterone; Recombinant Proteins; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 2002 |
In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone.
Topics: Alkaline Phosphatase; Animals; Cell Line; Enzyme Induction; Hormone Antagonists; Mifepristone; Norpregnadienes; Progestins; Protein Binding; Rabbits; Receptors, Glucocorticoid; Receptors, Progesterone | 2004 |
Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Apoptosis; Carcinogens; Cell Proliferation; Disease Progression; Female; Hormone Antagonists; Mammary Neoplasms, Experimental; Mifepristone; Norpregnadienes; Progesterone Congeners; Progestins; Rats; Rats, Sprague-Dawley | 2007 |
The activities of progesterone receptor isoform A and B are differentially modulated by their ligands in a gene-selective manner.
Topics: Adenoviridae; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Division; Collagen; Drug Combinations; Female; Fluorescent Antibody Technique; Hormone Antagonists; Humans; Laminin; Ligands; Mifepristone; Neoplasm Invasiveness; Norpregnadienes; Polymerase Chain Reaction; Progesterone; Protein Isoforms; Proteoglycans; Receptors, Progesterone; Transfection; Tumor Cells, Cultured; Wound Healing | 2008 |
Progesterone receptor antagonist CDB-4124 increases depression-like behavior in mice without affecting locomotor ability.
Topics: Animals; Depression; Depression, Postpartum; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Finasteride; Locomotion; Mice; Mice, Inbred DBA; Mifepristone; Norpregnadienes; Premenstrual Syndrome; Progesterone; Receptors, Progesterone; Single-Blind Method; Swimming | 2011 |
Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estrenes; Female; Furans; Hormone Antagonists; Humans; Inhibitory Concentration 50; Mifepristone; Norpregnadienes; Paclitaxel | 2014 |
Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Antigens, CD34; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Hormone Antagonists; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Medroxyprogesterone Acetate; Methylnitrosourea; Mice; Mifepristone; Neovascularization, Pathologic; Norpregnadienes; Progesterone; Progestins; Rats; Receptors, Estrogen; Receptors, Progesterone; Time Factors | 2016 |
Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
Topics: Animals; BRCA1 Protein; Breast Neoplasms; Carcinogenesis; Disease Models, Animal; Epithelial Cells; Female; Humans; Mammary Glands, Animal; Mastectomy; Mice; Mifepristone; Norpregnadienes; Receptors, Progesterone; Stromal Cells; Tumor Microenvironment | 2021 |